Abstract
ObjectiveVerinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad in combination with febuxostat...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have